Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
28 juin 2023 08h00 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
31 mai 2023 16h15 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
11 mai 2023 16h05 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates
08 mai 2023 16h05 HE
|
Viracta Therapeutics, Inc.
Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023...
Viracta Therapeutics Announces Departure of Chief Medical Officer
02 mai 2023 16h05 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
19 avr. 2023 16h30 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
13 mars 2023 16h05 HE
|
Viracta Therapeutics, Inc.
Pivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open at 70 sites globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 expected in the...
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
08 mars 2023 16h05 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
07 févr. 2023 16h05 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma
19 janv. 2023 08h30 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...